Valuation
- Market cap
- 1,710,556,000
- Revenue TTM
- $30,409,000
- Net income TTM
- $840,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 576,025
- Avg volume
- 893,518
- Day's range
- $15.60 – $16.20
- Shares out
- 107,447,000
- Stochastic %K
- 21%
- Beta
- 0.48
- Analysts
- Strong Sell
- Price target
- $18.00
Company profile
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung,...
Show more
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- (650) 446-6630
- Website
- https://www.freenome.com
- Address
- 3300 Marina Boulevard, Brisbane, United States
Latest news
No headlines yet.
